MENU
Showcases Stock ranks Forex

Aslan Pharmaceuticals Ltd ADR (ASLN)
0.631  -0.004 (-0.63%) 03-27 16:00
Open: 0.629 Pre. Close: 0.635
High: 0.65 Low: 0.6098
Volume: 215,585 Market Cap: 11(M)
Stock Technical Analysis
Overall:     
Target: Six months: 1.69
One year: 2.44
Support: Support1: 0.40
Support2: 0.33
Resistance: Resistance1: 1.44
Resistance2: 2.09
Pivot: 0.74
Moving Averages: MA(5): 0.65
MA(20): 0.73
MA(100): 0.67
MA(250): 1.95
MACD: MACD(12,26): 0.01
Signal(12,26,9): 0.03
%K %D: %K(14,3): 5.58
%D(3): 6.34
RSI: RSI(14): 48.40
52-Week: High: 4.69
Low: 0.392
Change(%): -76.1
Average Vol(K): 3-Month: 1026
10-Days: 878
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.651 - 0.655 0.655 - 0.659
Low: 0.6 - 0.604 0.604 - 0.608
Close: 0.622 - 0.629 0.629 - 0.637
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ ASLN ] has closed above bottom band by 38.8%. Bollinger Bands are 112.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
Company profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Stock chart
Stock News
Thu, 28 Mar 2024
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Large Growth in Short Interest - Defense World

Fri, 22 Mar 2024
ASLN Stock Quote Price and Forecast - CNN

Fri, 22 Mar 2024
Equities Analysts Set Expectations for ASLAN Pharmaceuticals Limited's FY2024 Earnings (NASDAQ:ASLN) - Defense World

Tue, 12 Mar 2024
Healthcare Stocks on the Move Tuesday: RGLS, LTRN, VIRX, GLSI, LEXX, CRBU, ASLN, VRPX - InvestorsObserver

Wed, 06 Mar 2024
ASLAN's Eblasakimab shows promise in COPD treatment study - Investing.com

Tue, 16 Jan 2024
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.62% By Investing.com - Investing.com

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 17.60
Shares Float (M) 370.17
% Held by Insiders 0.05
% Held by Institutions 14.90
Shares Short (K) 19
Shares Short Prior Month (K) 59
Stock Financials
EPS -3.000
Book Value (p.s.) -0.050
Profit Margin
Operating Margin -369.02
Return on Assets (ttm) -47.2
Return on Equity (ttm) -426.6
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share 0.682
EBITDA (p.s.) -2.515
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)
Stock Valuation
PE Ratio -0.21
PEG Ratio
Price to Book value -12.62
Price to Sales 0.93
Price to Cash Flow
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android